SIGMAR1 and breast carcinoma: Accordingly, scintigraphy with a moderately-selective Sig1R ligand (N-[2-(1′-Piperidinyl) Ethyl]-3-123I-Iodo-4-Methoxybenzamide) on patients with primary breast cancer revealed that the ligand was specifically retained within the tumor site, but not in healthy tissues (Caveliers et al., 2001).